Health Care · Surgical & Medical Instruments & Apparatus · Nasdaq · CIK 1531177 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $5.34Day +0.75%Mkt cap $291M1Y +54.3%Off 52W high −42.2%Vol (1Y) 82.4%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,259 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest1.5% of sh out |
| Days to cover5.0d |
| 13F net flow (QoQ)+6.37% |
| Top-10 13F concentration70.8% |
| Next report (est.)2026-08-05 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$79.6M |
| Earnings (TTM)-$37.3M |
| ROE−50.7% |
| Net margin−49.7% |
| ROIC−311.8% |
| Debt / equity0.63× |
| Sales growth 3Y2.7% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−32.7% |
| 1Y+54.3% |
| 3Y−39.3% |
| 5Y−85.3% |
| Since incept. (ann.)−30.2% |
Total return through 2026-07-29 · series begins 2021-07-16. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)82.4% |
| Ann. volatility (3Y)97.1% |
| Sharpe (1Y)0.91 |
| Sharpe (3Y)0.38 |
| Max drawdown (1Y)−61.9% |
| Max drawdown (3Y)−85.3% |
| Beta (3Y vs SPY)4.05 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| Long Focus Capital Management, LLC | 3.6M | $14M | 6.61% | +9.2% |
| BlackRock, Inc. | 2.8M | $11M | 5.20% | +5.9% |
| Pathstone Holdings, LLC | 2.4M | $9M | 4.41% | +233.7% |
| Americana Partners, LLC | 1.7M | $6M | 3.09% | +21.8% |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.5M | $5M | 2.67% | new |
| B Group, Inc. | 970,000 | $4M | 1.78% | +5.4% |
| GEODE CAPITAL MANAGEMENT, LLC | 915,444 | $3M | 1.68% | +3.9% |
| STATE STREET CORP | 835,028 | $3M | 1.53% | +13.2% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-06 | −$0.24 | — | $19.7M | +12.5% |
| 2025-12-31 | 2026-03-04 | — | — | $20.4M | +6.9% |
| 2025-09-30 | 2025-11-06 | −$0.16 | — | $19.9M | −1.2% |
| 2025-06-30 | 2025-08-07 | −$0.23 | — | $19.6M | −8.5% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-05 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Surgical Glaucoma 98% · Dry Eye 2%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
